Who we are
Inhalation is our entire focus. Whether you’re working on small or large molecules, for a small biotech or large pharmaceutical company, we are here to support you at every stage of the development pathway.
Find out more
What we offer
Whether you’re working on small or large molecules, our teams are here to support you at every stage of the development pathway.
Whether you’re a small biotech or large pharmaceutical company, we can help you bring your inhaled products to market.
Our device technology and capabilities
We are one of the few companies globally that have developed dry powder inhalers (DPI), pressurised metered dose inhalers (pMDI) and nebulisers to deliver a broad range of complex inhaled therapies.
Our formulation and device technology has contributed to the success of eleven inhaled medicines, launched by our partners and licensees.
Our investor centre where you can find the latest financial information.
Our success ensures that we will deliver long-term value for our shareholders and for society.
We have a focused service offering to support customers and partners through the development lifecycle: from the laboratory to full-scale commercialisation
We have a focused service offering to support customers and partners throughout the development lifecycle
We are resolutely pursuing our vision to be the industry-leading inhaled drug device development specialist.
The large global CDMO market presents an attractive opportunity, with small and large companies looking for specialist technologies, expertise and quality to help develop their products.
Our partners and customers
Our wide partnership and customer base enables us to create the best outcomes for programmes and patients.
Board and Leadership team
Our Board members are committed to a clear, strategic vision for the Group.
Skyepharma is part of the Vectura Group of Companies
Stock exchange announcements
Financial news and announcements.
RNS email alerts
Subscribe and keep up-to-date with the latest financial information.
Presentations and webcasts
A selection of presentations and webcasts.
Our financial year, previous successes and clear strategies for the future
Our commitment to the principles of good governance enables us to deliver a clear refocused investment strategy.
Financial calendar and events
Meetings and events throughout the financial year.
Meetings and voting
The date and proposed resolutions for our next general meeting.
Share price information
Our up-to-the-minute share price as well as historical information.
Essential information for our shareholders.
Managing your shares
Important information on how to handle your shares.
Warning to shareholders
Share fraud warning and helpful numbers.
Analysts commenting on Vectura.
Vectura Group plc recommended All Share Merger with Skyepharma PLC
On 10 June 2016, an all-share merger of Vectura and Skyepharma PLC was completed.
Historical share offerings
Essential information for any shareholders in possession of historical shares.
News and media
The latest headlines from Vectura Group.
The latest updates and press releases from Vectura Group.
Connect and discover more about us, our people and our culture.
Our latest innovations and success stories.
A selection of resources introducing our business, culture and people.
Media contacts for Vectura
We create a dynamic and rewarding place to work with clear development opportunities.